My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Amneal Pharmaceuticals LLC
Amneal to Report Third Quarter 2025 Results on October 30, 2025
September 30, 2025
From
Amneal Pharmaceuticals LLC
Via
GlobeNewswire
Tickers
AMRX
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
September 26, 2025
From
Amneal Pharmaceuticals LLC
Via
GlobeNewswire
Tickers
AMRX
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
September 23, 2025
From
Amneal Pharmaceuticals LLC
Via
GlobeNewswire
Tickers
AMRX
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution
September 11, 2025
From
Amneal Pharmaceuticals LLC
Via
GlobeNewswire
Tickers
AMRX
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
September 04, 2025
From
Amneal Pharmaceuticals LLC
Via
GlobeNewswire
Tickers
AMRX
Amneal Reports Second Quarter 2025 Financial Results
August 05, 2025
From
Amneal Pharmaceuticals LLC
Via
GlobeNewswire
Tickers
AMRX
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
July 21, 2025
From
Amneal Pharmaceuticals LLC
Via
GlobeNewswire
Tickers
AMRX
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
July 21, 2025
From
Amneal Pharmaceuticals LLC
Via
GlobeNewswire
Tickers
AMRX
Amneal to Report Second Quarter 2025 Results on August 5, 2025
July 09, 2025
From
Amneal Pharmaceuticals LLC
Via
GlobeNewswire
Tickers
AMRX
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
June 25, 2025
From
Amneal Pharmaceuticals LLC
Via
GlobeNewswire
Tickers
AMRX
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
June 12, 2025
From
Amneal Pharmaceuticals LLC
Via
GlobeNewswire
Tickers
AMRX
Amneal to Participate at Upcoming Investor Conferences in June
May 29, 2025
From
Amneal Pharmaceuticals LLC
Via
GlobeNewswire
Tickers
AMRX
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
May 15, 2025
From
Amneal Pharmaceuticals LLC
Via
GlobeNewswire
Tickers
AMRX
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
May 08, 2025
From
Amneal Pharmaceuticals LLC
Via
GlobeNewswire
Tickers
AMRX
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.